Abstract
Amantadine extended release (ER) [GOCOVRI®], an NMDA receptor antagonist, is an important treatment option in the management of levodopa-induced dyskinesia (LID) and OFF episodes in patients with Parkinson’s disease (PD). Taken at bedtime, amantadine ER provides low plasma levels overnight and high plasma concentrations during the waking day (i.e. delayed release). In randomized, double-blind, placebo-controlled phase III trials in adults with PD, once-daily amantadine ER was effective in improving LID, reducing OFF time and increasing ON time without troublesome dyskinesia, compared with placebo. Control of motor complications with amantadine ER was evident throughout the day, with fewer transitions between motor states. The clinical benefits of amantadine ER in reducing the duration and impact of dyskinesia and OFF episodes were durable with long-term treatment. Amantadine ER is generally well tolerated, including in the long term, with the majority of adverse events being mild or moderate in severity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
